Disease-modifying treatments in transthyretin amyloid cardiomyopathy: a meta-analysis of randomized controlled trials

Back

ESC Professional Premium Access

Disease-modifying treatments in transthyretin amyloid cardiomyopathy: a meta-analysis of randomized controlled trials

Session: Drug therapy for heart failure: what is new?

Topic: Pharmacotherapy

Speaker: Doctor C. Tsai (Taipei, TW)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Cheng-Hsuan Tsai

National Taiwan University Hospital, Taipei (Taiwan)

0 follower

8 more presentations in this session

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

Speaker: Doctor H. Lu (Boston, US)

Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

Speaker: Professor M. Crespo-Leiro (A Coruna, ES)

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

Speaker: Doctor R. Aggarwal (Boston, US)

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Speaker: Doctor J. Butt (Copenhagen, DK)

Long-term follow-up of the TRED-HF trial

Speaker: Miss L. Cheng (London, GB)

Access the full session

Drug therapy for heart failure: what is new?

Speakers: Doctor C. Tsai, Doctor H. Lu, Professor M. Crespo-Leiro, Doctor R. Aggarwal, Doctor J. Butt...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources